Drug Trial Radar · NCT07708831
Trial on Single/Multiple Ascending Doses for Safety, PK and PD for CBP-0276 in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
64
Actual
Start
Sep 4, 2025
Primary completion
Feb 16, 2026
Study completion Apr 30, 2026
Sponsor
- Lead sponsor
- Clarent Biopharma, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years, up to 63 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A double-blind, randomized, placebo-controlled, single and multiple ascending dose study with food effect to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of CBP-0276. Incidence of potential related adverse events and laboratory abnormalities produced after investigational product vs. placebo administration will be identified and analyzed. 64 subjects in total, 32 subjects in Part 1 (Single Dose Ascending:SAD) and 32 subjects in Part 2 (Multiple Dose Ascending:MAD). Healthy voluntieers (male and women), ≥ 18 to ≤ 64 years with at least least 50% of the population ≥ 45 years old will be included after sign of informed consent. Full sample in SAD and MAD will be divided in 4 subcohorts each. Subcohorts will receive 100mgQD of CBP-0276 or placebo (6:2), 200mgQD of CBP-0276 or placebo (6:2), 200mgBID of CBP-0276 or placebo (6:2) or 400mg QD of CBP-0276 or placebo (6:2). On MAD subjects will receive CBP-0276 during 14 days. The total duration of study participation for each subject (from the screening visit to the end-of-study visit) on SAD will be approximately 36 days for cohorts S1, S3, and S4 and approximately 43 days for cohort S2. The total duration of study participation for each subject (from the screening visit to the end-of-study visit) on MAD will be approximately 49 days for the M1, M2, M3, and M4 cohorts. After CBP-0276 administration plasma samples will be obtained to evaluate PK parameteres (AUC0-∞, AUC0-24, AUC0-tlast, AUC0-τ, %AUCextrap, Cmax, Ctrough, tlag, tmax.ss, t1/2, λz, MRT0-∞, CL/F, Vz/F, %Fluctuation, ARABC and ARCmax in plasma).
Conditions
- Healthy Volunteers
Interventions
CBP-0276 AcetateDrug
CBP-0276 Acetate
Placebo for CBP-0276 AcetateDrug
Placebo for CBP-0276 Acetate: 100 mg of microcrystalline cellulose microcrystals (MCC)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse eventsTime frame: 36 hours after randomization for SAD and 15 days after randomization for for MAD
- Severity of adverse eventsTime frame: 36 hours after randomization for SAD and 15 days after randomization for for MAD
- Alterations systolic blood pressureTime frame: 36 hours after randomization for SAD and 15 days after randomization for for MAD
- Time until first adverse eventTime frame: 36 hours after randomization for SAD and 15 days after randomization for for MAD
- Duration of adverse events.Time frame: 36 hours after randomization for SAD and 15 days after randomization for for MAD
- Duration of the QRT interval in electrocardiogramTime frame: evalution o QRT by electro36 hours after randomization for SAD and 15 days after randomization for for MAD
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Innovacion y Desarrollo en Ciencias de la Salud (IDeCSa)
Mexico City, Mexico
Centro de Investigación Clínica y Medicina Traslacional (CiMeT)
Guadalajara, Jalisco, Mexico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.